World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
116
Citations
73017
World Ranking
4271
National Ranking
2334

Overview

D. Ross Camidge is affiliated with the University of Colorado Anschutz Medical Campus in the United States. Their research is primarily situated within the field of Medicine, with a focus on subfields including Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

Their work mainly concentrates on topics related to Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, as well as Gastric Cancer Management and Outcomes.

D. Ross Camidge has contributed extensively to several scientific journals. Frequent publication venues include Journal of Thoracic Oncology, Journal of Clinical Oncology, Annals of Oncology, Clinical Lung Cancer, and Lung Cancer.

Their collaborative network includes frequent co-authors such as Enriqueta Felip, Tejas Patil, James Chih-Hsin Yang, Sanjay Popat, and Alexander Drilon.

Among recent publications authored by Camidge are:

  • Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial (2020), Journal of Clinical Oncology
  • Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial (2021), Journal of Thoracic Oncology

Additional relevant papers from related researchers include:

  • Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study (2020), Annals of Oncology
  • Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration (2020), Nature Medicine
  • Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial (2021), Cancer Discovery

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer

    Robert C. Doebele;Amanda B. Pilling;Dara L. Aisner;Tatiana G. Kutateladze

  • Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

    Daniel R. Gomez;Chad Tang;Jianjun Zhang;George R. Blumenschein

  • Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

    Daniel R Gomez;George R Blumenschein;J Jack Lee;Mike Hernandez

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Acquired resistance to TKIs in solid tumours: learning from lung cancer

    D. Ross Camidge;William Pao;Lecia V. Sequist

  • Response assessment criteria for brain metastases: proposal from the RANO group

    Nancy U Lin;Eudocia Q Lee;Hidefumi Aoyama;Igor J Barani

  • Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer

    D. Ross Camidge;Hye Ryun Kim;Myung Ju Ahn;James Chih Hsin Yang

  • Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

    Lecia V. Sequist;Jean Charles Soria;Jonathan W. Goldman;Heather A. Wakelee

  • Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

    Benjamin J. Solomon;Benjamin Besse;Benjamin Besse;Todd M. Bauer;Enriqueta Felip

  • Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

    Andrew J. Weickhardt;Benjamin Scheier;Joseph Malachy Burke;Gregory Gan

  • Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

    Alice T Shaw;Leena Gandhi;Shirish Gadgeel;Gregory J Riely

  • Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

    Jennifer L. Spratlin;Roger B. Cohen;Matthew Eadens;Lia Gore

Frequent Co-Authors

Robert C. Doebele
Robert C. Doebele University of Colorado Denver
Alice T. Shaw
Alice T. Shaw Harvard University
Benjamin Solomon
Benjamin Solomon Peter MacCallum Cancer Centre
Sai-Hong Ignatius Ou
Sai-Hong Ignatius Ou University of California, Irvine
Shirish M. Gadgeel
Shirish M. Gadgeel University of Michigan–Ann Arbor
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Lecia V. Sequist
Lecia V. Sequist Harvard University
Paul A. Bunn
Paul A. Bunn University of Colorado Boulder
Scott N. Gettinger
Scott N. Gettinger Yale University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medical careers, there are a variety of flexible online options to advance your education and broaden your opportunities. Many nurses start their journey through cost-effective programs; consider the most affordable accredited online rn to bsn programs to complete your bachelor’s degree and open doors to leadership roles.

If you hold a non-nursing bachelor’s degree and want to shift careers, there are online direct entry msn programs for non-nurses that allow a fast-track path toward advanced nursing credentials. Entry requirements and program lengths vary, so researching your options is crucial.

For students looking for a smoother admission process, explore whats the easiest nursing program to get into? to find schools offering supportive entry requirements and flexible learning.

Not all healthcare roles require patient care—those interested in administration might opt for careers in medical billing and coding. Research medical billing and coding schools with financial aid to find accredited programs that can be completed from home with financial support options.

Best Scientists Citing D. Ross Camidge

Trending Scientists

Recently Published Articles